Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure

Journal of Cardiovascular Medicine

Volumn 8, Issue 9, 2007, Pages 675-682

  Del Sindaco, Donatella ^a   Pulignano, Giovanni ^b   Cioffi, Giovanni ^c   Tarantini, Luigi ^d   Di Lenarda, Andrea ^e   De Feo, Stefania ^f   Opasich, Cristina ^f   Minardi, Giovanni ^b   Giovannini, Ezio ^b   Leggio, Francesco ^a  

^a INRCA   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c Casa di Cura Villa Bianca   (Italy)

^d SAN MARTINO HOSPITAL   (Italy)

^e Azienda Ospedaliera Ospedali Riuniti   (Italy)

^f IRCCS   (Italy)

Author keywords

Carvedilol; Diabetes mellitus; Elderly; Ventricular remodelling

Indexed keywords

CARVEDILOL; CREATININE; GLUCOSE; HEMOGLOBIN;

AGED; ARTICLE; BRADYCARDIA; BRONCHOSPASM; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIABETES MELLITUS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; GROUPS BY AGE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE VOLUME; HOSPITALIZATION; HUMAN; INCIDENCE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; OUTCOME ASSESSMENT; PROGNOSIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; SYSTOLIC DYSFUNCTION;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CARBAZOLES; DIABETES MELLITUS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERGLYCEMIA; MALE; PROPANOLAMINES; TREATMENT OUTCOME;

EID: 34548049802     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000285316.71057.26     Document Type: Article

References (49)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241:2035-2038.
2. Aronow WS, Ahn C. Incidence of heart failure in 2737 older persons with and without diabetes mellitus. Chest 1999; 115:867-868.
3. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996; 77:1017-1020.
4. Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999; 106:605-612.
5. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24:1614-1619.
6. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy [abstract]. Circulation 1996; 94 (Suppl):I-664.
7. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3:469-479.
8. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11 942 elderly patients with heart failure. Am J Med 2002; 113:650-656.
9. Opasich C, Boccanelli A, Cafiero M, Cirrincione V, Del Sindaco D, Di Lenarda A, et al., for the BRING-UP 2 Investigators. Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: results of the BRING-UP 2 Study. Eur J Heart Fail 2006; 8:649-657.
10. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146:848-853.
11. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529-1538.
12. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11:1258-1265.
13. Gheorghiade M, Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation 2002; 106:394-398.
14. Reis SE, Holubkov R, Edmundowicz D, McNamara DM, Zell KA, Detre KM, et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997; 30:733-738.
15. Chin MH, Wang JC, Zhang JX, Sachs GA, Lang RM. Differences among geriatricians, general internists, and cardiologists in the care of patients with heart failure: a cautionary tale of quality assessment. J Am Geriatr Soc 1998; 46:1349-1354.
16. Philbin EF, Jenkins PL. Differences between patients with heart failure treated by cardiologists, internists, family physicians, and other physicians: analysis of a large, statewide database. Am Heart J 2000; 139:491-496.
17. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14:489-494.
18. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955-959.
19. Refsgaard J, Thomsen C, Andreasen F, Gotzsche O. Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. Eur J Heart Fail 2002; 4:445-453.
20. Ferrua S, Bobbio M, Catalano E, Grassi G, Massobrio N, Pinach S, et al. Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? J Card Fail 2005; 11:590-594.
21. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans CM, Bailey KR, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98:2282-2289.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383.
23. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367.
24. Miyatake K, Izumi S, Okamoto M, Kinoshita N, Asonuma H, Nakagawa H, et al. Semiquantitative grading of severity of mitral regurgitation by real-time two-dimensional Doppler flow imaging technique. J Am Coll Cardiol 1986; 7:82-88.
25. Mohacsi P, Fowler MB, Krum H, Tendera M, Coats AJ, Rouleau JJ, et al. Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study [abstract]. Circulation 2001; 104 (Suppl):II-754.
26. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effect of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283:1295-1302.
27. Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, et al. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail 2001; 7:4-12.
28. Pulignano G, Del Sindaco D, Tavazzi L, Lucci D, Gorini M, Leggio F, et al., for the IN-CHF Investigators. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 2002; 143:45-55.
29. Mills GA, Horn JR. Beta-blockers and glucose control. Drug Intell Clin Pharm 1985; 19:246-251.
30. Houston MC. Adverse effects of antihypertensive drug therapy on glucose intolerance. Cardiol Clin 1986; 4:117-135.
31. Deacon SP, Karunanayake A, Barnett D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. BMJ 1977; 2:1255-1257.
32. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157:1681-1686.
33. Greene DA. Acute and chronic complications of diabetes mellitus in older patients. Am J Med 1986; 80:39-53.
34. Cahill GF Jr. Hyperglycemic hyperosmolar coma: a syndrome almost unique to the elderly. J Am Geriatr Soc 1983; 31:103-105.
35. Bobbio M, Ferrua S, Opasich C, Porcu M, Lucci D, Scherillo M, et al., for the BRING-UP Investigators. Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. J Card Fail 2003; 9:192-202.
36. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al., for the Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.
37. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al., for the GEMINI Investigators. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236.
38. Coletta AP, Cleland JG, Freemantle N, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure Meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail 2004; 6:673-676.
39. Nodari S, Metra M, Dei Cas A, Dei Cas L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Eur J Heart Fail 2003; 5:803-809.
40. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38:421-428.
41. De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 2004; 25:656-662.
42. Suskin N, McKelvie RS, Burns RJ, Latini R, Pericak D, Probsfield J, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000; 21:1368-1375.
43. Opasich C, Cafiero M, Scherillo M, De Feo S, Caputo F, Gonzini L, et al., for the TEMISTOCLE Investigators. Impact of diabetes on the current inhospital management of heart failure. From the TEMISTOCLE study. Ital Heart J 2003; 4:685-694.
44. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, et al., for the MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005; 149:159-167.
45. Bell DS, Lukas MA, Holdbrook FK, Fowler MB. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 2006; 22:287-296.
46. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al., for the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26:215-225.
47. Vitagliano G, Curtis JP, Concato J, Feinstein AR, Radford MR, Krumholz HM. Association between functional status and use and effectiveness of beta-blocker prophylaxis in elderly survivors of acute myocardial infarction. J Am Geriatr Soc 2004; 52:495-501.
48. Pulignano G, Del Sindaco D, Tavazzi L, Boccanelli A, Di Lenarda A, Gonzini L, et al., for the BRING-UP 2 Investigators. Safety of beta-blockade on functional ability, cognitive function and depression in elderly heart failure patients. Data from a large nationwide study: the BRING-UP 2 [abstract]. Eur J Heart Fail 2004; 3 (Suppl 1):115.
49. Cioffi G, Tarantini L, De Feo S, Pulignano G, Del Sindaco D, Stefenelli C, et al. Pharmacological left ventricular reverse remodeling in elderly patients receiving optimal therapy for chronic heart failure. Eur J Heart Fail 2005; 7:1040-1048.